Literature DB >> 23883836

Cyclosporin A inhibits the propagation of influenza virus by interfering with a late event in the virus life cycle.

Itsuki Hamamoto1, Kazuhiro Harazaki, Naohiko Inase, Hiroshi Takaku, Masato Tashiro, Norio Yamamoto.   

Abstract

Influenza is a global public health problem that causes a serious respiratory disease. Influenza virus frequently undergoes amino acid substitutions, which result in the emergence of drug-resistant viruses. To control influenza viruses that are resistant to currently available drugs, it is essential to develop new antiviral drugs with a novel molecular target. Here, we report that cyclosporin A (CsA) inhibits the propagation of influenza virus in A549 cells by interfering with a late event in the virus life cycle. CsA did not affect adsorption, internalization, viral RNA replication, or synthesis of viral proteins in A549 cells, but inhibited the step(s) after viral protein synthesis, such as assembly or budding. In addition, siRNA-mediated knockdown of the expression of the major CsA targets, namely cyclophilin A (CypA), cyclophilin B (CypB), and P-glycoprotein (Pgp), did not inhibit influenza virus propagation. These results suggest that CsA inhibits virus propagation by mechanism(s) independent of the inhibition of the function of CypA, CypB, and Pgp. CsA may target an unknown molecule that works as a positive regulator in the propagation of influenza virus. Our findings would contribute to the development of a novel anti-influenza virus therapy and clarification of the regulatory mechanism of influenza virus multiplication.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23883836     DOI: 10.7883/yoken.66.276

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  12 in total

1.  Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance.

Authors:  Chunlong Ma; Fang Li; Rami Ghassan Musharrafieh; Jun Wang
Journal:  Antiviral Res       Date:  2016-07-28       Impact factor: 5.970

2.  Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga.

Authors:  Abhilash I Chiramel; Logan Banadyga; Jonathan D Dougherty; Darryl Falzarano; Cynthia Martellaro; Dominique Brees; R Travis Taylor; Hideki Ebihara; Sonja M Best
Journal:  J Infect Dis       Date:  2016-08-10       Impact factor: 5.226

Review 3.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

4.  Proteomic identification of cyclophilin A as a potential biomarker and therapeutic target in oral submucous fibrosis.

Authors:  Yao Yuan; Xiaohui Hou; Hui Feng; Rui Liu; Hao Xu; Wang Gong; Jing Deng; Chongkui Sun; Yijun Gao; Jieying Peng; Yingfang Wu; Jiang Li; Changyun Fang; Qianming Chen
Journal:  Oncotarget       Date:  2016-09-13

Review 5.  Antivirals for Respiratory Viral Infections: Problems and Prospects.

Authors:  Qiang Liu; Yuan-Hong Zhou; Feng Ye; Zhan-Qiu Yang
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119

Review 6.  Drug repurposing for new, efficient, broad spectrum antivirals.

Authors:  Moisés García-Serradilla; Cristina Risco; Beatriz Pacheco
Journal:  Virus Res       Date:  2019-02-19       Impact factor: 3.303

Review 7.  Cyclophilin A as a target in the treatment of cytomegalovirus infections.

Authors:  Ashwaq A Abdullah; Rasedee Abdullah; Zeenathul A Nazariah; Krishnan N Balakrishnan; Faez Firdaus J Abdullah; Jamilu A Bala; Mohd-Azmi Mohd-Lila
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

Review 8.  Cyclophilins and cyclophilin inhibitors in nidovirus replication.

Authors:  Adriaan H de Wilde; Uyen Pham; Clara C Posthuma; Eric J Snijder
Journal:  Virology       Date:  2018-07-12       Impact factor: 3.616

9.  A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.

Authors:  Vaishali M Patil; Shipra Singhal; Neeraj Masand
Journal:  Life Sci       Date:  2020-05-11       Impact factor: 5.037

Review 10.  The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections.

Authors:  Paulina Glowacka; Lidia Rudnicka; Olga Warszawik-Hendzel; Mariusz Sikora; Mohamad Goldust; Patrycja Gajda; Anna Stochmal; Leszek Blicharz; Adriana Rakowska; Malgorzata Olszewska
Journal:  Biology (Basel)       Date:  2020-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.